2,350 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Purchased by Moran Wealth Management LLC

Moran Wealth Management LLC acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 4th quarter, Holdings Channel reports. The firm acquired 2,350 shares of the biotechnology company’s stock, valued at approximately $227,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. KB Financial Partners LLC boosted its position in shares of BioMarin Pharmaceutical by 51.3% in the 3rd quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 118 shares in the last quarter. Lindbrook Capital LLC boosted its stake in BioMarin Pharmaceutical by 259.8% in the 4th quarter. Lindbrook Capital LLC now owns 385 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 278 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in BioMarin Pharmaceutical by 135.3% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 249 shares in the last quarter. First Horizon Advisors Inc. increased its stake in BioMarin Pharmaceutical by 33.3% during the 4th quarter. First Horizon Advisors Inc. now owns 576 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 144 shares in the last quarter. Finally, Allworth Financial LP raised its holdings in BioMarin Pharmaceutical by 54.9% in the fourth quarter. Allworth Financial LP now owns 604 shares of the biotechnology company’s stock worth $58,000 after buying an additional 214 shares during the last quarter. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, Director Jean Jacques Bienaime sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $90.35, for a total value of $90,350.00. Following the completion of the sale, the director now owns 562,203 shares of the company’s stock, valued at $50,795,041.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other BioMarin Pharmaceutical news, Director Jean Jacques Bienaime sold 1,000 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $90.35, for a total value of $90,350.00. Following the sale, the director now owns 562,203 shares in the company, valued at $50,795,041.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP George Eric Davis sold 1,850 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $85.01, for a total transaction of $157,268.50. Following the sale, the executive vice president now directly owns 56,157 shares of the company’s stock, valued at approximately $4,773,906.57. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 110,079 shares of company stock worth $9,528,436. Insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Trading Down 1.8 %

Shares of NASDAQ BMRN traded down $1.46 during trading hours on Thursday, hitting $78.94. 117,774 shares of the company traded hands, compared to its average volume of 1,439,330. The company’s 50 day moving average price is $85.82 and its 200 day moving average price is $88.92. BioMarin Pharmaceutical Inc. has a 12 month low of $76.02 and a 12 month high of $99.56. The stock has a market capitalization of $14.99 billion, a price-to-earnings ratio of 75.14, a price-to-earnings-growth ratio of 1.27 and a beta of 0.34. The company has a current ratio of 2.74, a quick ratio of 1.70 and a debt-to-equity ratio of 0.12.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Wednesday, April 24th. The biotechnology company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.12. BioMarin Pharmaceutical had a net margin of 8.31% and a return on equity of 5.34%. The business had revenue of $648.83 million for the quarter, compared to analysts’ expectations of $649.75 million. On average, equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post 1.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on BMRN. Morgan Stanley lowered their target price on shares of BioMarin Pharmaceutical from $115.00 to $112.00 and set an “overweight” rating on the stock in a research note on Friday, April 26th. Scotiabank lifted their target price on BioMarin Pharmaceutical from $83.00 to $85.00 and gave the company a “sector perform” rating in a research report on Thursday, April 25th. Canaccord Genuity Group reduced their price objective on shares of BioMarin Pharmaceutical from $91.00 to $89.00 and set a “hold” rating for the company in a research note on Friday, April 26th. Wells Fargo & Company boosted their price objective on BioMarin Pharmaceutical from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Finally, Robert W. Baird decreased their target price on BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 30th. Seven equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $107.79.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.